PubRank

Nancy L Weigel

Author PubWeight™ 58.38‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005 2.14
2 Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006 1.90
3 Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 2006 1.85
4 International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 2006 1.60
5 Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol 2003 1.51
6 Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol 2005 1.41
7 Repressors of androgen and progesterone receptor action. J Biol Chem 2003 1.35
8 Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 2009 1.35
9 Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res 2011 1.32
10 Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem 2006 1.31
11 Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther 2013 1.28
12 Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol 2005 1.25
13 Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation. Biofactors 2009 1.13
14 Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol 2008 1.12
15 Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate 2005 1.06
16 Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol 2008 1.03
17 A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab 2004 1.03
18 Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol 2012 1.02
19 Coactivator selective regulation of androgen receptor activity. Steroids 2009 1.02
20 p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 2003 1.00
21 Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids 2013 0.99
22 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 2009 0.99
23 Vitamin D and prostate cancer. Exp Biol Med (Maywood) 2004 0.99
24 Vitamin D and prostate cancer. J Androl 2002 0.97
25 Mechanistic differences in the activation of estrogen receptor-alpha (ER alpha)- and ER beta-dependent gene expression by cAMP signaling pathway(s). J Biol Chem 2003 0.97
26 The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J Biol Chem 2004 0.96
27 Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. Steroids 2007 0.95
28 Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res 2009 0.94
29 c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol 2005 0.93
30 Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res 2013 0.92
31 Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res 2004 0.91
32 Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate 2005 0.91
33 Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. J Biol Chem 2005 0.91
34 AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat 2014 0.90
35 Novel phosphorylation target in the serum response factor MADS box regulates alpha-actin transcription. Biochemistry 2003 0.90
36 EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol Cancer Ther 2009 0.90
37 Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J 2006 0.90
38 Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol 2012 0.89
39 Constitutively active FOXO1a and a DNA-binding domain mutant exhibit distinct co-regulatory functions to enhance progesterone receptor A activity. J Mol Endocrinol 2007 0.88
40 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology 2010 0.88
41 Identification of a transferable two-amino-acid motif (GT) present in the C-terminal tail of the human lutropin receptor that redirects internalized G protein-coupled receptors from a degradation to a recycling pathway. Mol Endocrinol 2002 0.87
42 Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids 2005 0.87
43 Phosphorylation: a fundamental regulator of steroid receptor action. Trends Endocrinol Metab 2013 0.86
44 Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400. Mol Endocrinol 2009 0.85
45 Regulation of progesterone receptor activity by cyclin dependent kinases 1 and 2 occurs in part by phosphorylation of the SRC-1 carboxyl-terminus. Int J Biochem Cell Biol 2011 0.85
46 PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3). Steroids 2007 0.84
47 Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol 2005 0.82
48 A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol 2002 0.82
49 1α,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest. Prostate 2011 0.81
50 Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089). Bone 2004 0.81
51 Analysis of receptor phosphorylation. Methods Enzymol 2003 0.80
52 A standards-based, peer-reviewed teaching award to enhance a medical school's teaching environment and inform the promotions process. Acad Med 2012 0.80
53 Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3. Prostate 2003 0.79
54 1alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate 2004 0.78
55 Molecular analysis of the androgen receptor in ten prostate cancer specimens obtained before and after androgen ablation. J Androl 2003 0.78
56 The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. Endocrinology 2014 0.77
57 A role for site-specific phosphorylation of mouse progesterone receptor at serine 191 in vivo. Mol Endocrinol 2014 0.75